Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infection Among Bangladeshi Children: A Protocol for a Phase IIIb Trial
Author(s) -
Katherine Theiss-Nyland,
Firdausi Qadri,
Rachel Colin-Jones,
Khalequ Zaman,
Farhana Khanam,
Xinxue Liu,
Merryn Voysey,
Arifuzzaman Khan,
Nazmul Hasan,
Fahim Ashher,
Yama F Mujadidi,
Andrew J. Pollard,
John D. Clemens
Publication year - 2019
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciy1107
Subject(s) - typhoid fever , medicine , population , conjugate vaccine , environmental health , sanitation , public health , randomized controlled trial , protocol (science) , government (linguistics) , informed consent , cluster (spacecraft) , family medicine , pediatrics , alternative medicine , surgery , immunology , immunization , virology , nursing , pathology , antigen , linguistics , philosophy , computer science , programming language
Typhoid fever illnesses are responsible for more than 100 000 deaths worldwide each year. In Bangladesh, typhoid fever is endemic, with incidence rates between 292-395 per 100 000 people annually. While considerable effort has been made to improve access to clean water and sanitation services in the country, there is still a significant annual typhoid burden, which particularly affects children. A typhoid conjugate vaccine (Vi-TCV) was recently prequalified by the World Health Organization and recommended for use, and offers the potential to greatly reduce the typhoid burden in Bangladesh.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom